Table 1.
Statin use prior to (and including) index date of cancer and comparison cohorts
| Variable | Cancer cohort | Comparison cohort |
| N=1731 | N=3462 | |
| Statin type, n (%) | ||
| Atorvastatin alone | 685 (39.6) | 1304 (37.8) |
| Fluvastatin alone | 13 (0.8) | 39 (1.1) |
| Pravastatin alone | 257 (14.8) | 525 (15.2) |
| Rosuvastatin alone | 1 (0.0) | 3 (0.0) |
| Simvastatin alone | 653 (37.7) | 1306 (37.8) |
| Two or more statins | 122 (7.0) | 285 (8.2) |
| DDD/day, median (IQR) | ||
| Atorvastatin | 1.00 (1.0–2.00) | 1.00 (1.00–2.00) |
| Fluvastatin | 0.67 (0.33–0.67) | 0.67 (0.33–0.67) |
| Pravastatin sodium | 1.33 (0.67–1.33) | 1.33 (0.67–1.33) |
| Rosuvastatin | 2.00 (1.00–2.00) | 2.00 (1.00–2.31) |
| Simvastatin | 0.67 (0.67–1.33) | 0.67 (0.67–1.33) |
| Time from first statin to index date (days), median (IQR) | 611 (336–901) | 616 (339–903) |
| Patients with breaks of ≥90 days in therapy, n (%) | 310 (17.9) | 888 (25.6) |
| Duration of breaks in therapy (days), median (IQR) | 136 (102–211) | 142 (104–232) |
DDD, defined daily dose.